Epidemiology, methodological quality, and reporting characteristics of systematic reviews and meta-analyses on coronavirus disease 2019: a cross-sectional study

Yuehong Chen, PhDa, Ling Li, PhDb, Qiuping Zhang, MDA, Huan Liu, MDA, Yupeng Huang, PhDa, Sang Lin, MDA, Geng Yin, PhDa, Qibing Xie, PhDa,∗

Abstract
During the coronavirus disease 2019 (COVID-19) pandemic, convenient accessibility and rapid publication of studies related to the ongoing pandemic prompted shorter preparation time for studies. Whether the methodological quality and reporting characteristics of published systematic reviews (SRs)/meta-analyses are affected during the specific pandemic condition is yet to be clarified. This study aimed to evaluate the epidemiology, methodological quality, and reporting characteristics of published SRs/meta-analyses related to COVID-19.

The Ovid Medline, Ovid Embase, Cochrane Library, and Web of Science electronic databases were searched to identify published SRs/meta-analyses related to the COVID-19 pandemic. Study screening, data extraction, and methodology quality assessment were performed independently by 2 authors. The methodology quality of included SRs/meta-analyses was evaluated using revised version of a measurement tool to assess SRs, and the reporting characteristics were assessed based on the preferred reporting items for SRs and meta-analyses guidelines.

A total of 47 SRs/meta-analyses were included with a low to critically low methodological quality. The median number of days from the date of literature retrieval to the date that the study was first available online was 21 days; due to the limited time, only 7 studies had study protocols, and the studies focused on a wide range of COVID-19 topics. The rate of compliance to the preferred reporting items for SRs and meta-analyses checklists of reporting characteristics ranged from 14.9% to 100%. The rate of compliance to the items of protocol and registration, detailed search strategy, and assessment of publication bias was less than 50%.

SRs/meta-analyses on COVID-19 were poorly conducted and reported, and thus, need to be substantially improved.

Abbreviations: AMSTAR = a measurement tool to assess systematic reviews, COVID-19 = coronavirus disease 2019, PRISMA = preferred reporting items for systematic reviews and meta-analyses, RCT = randomized controlled trial, SRs = systematic reviews.

Keywords: coronavirus disease 2019, meta-analysis, preferred reporting items for systematic reviews and meta-analyses, revised version of a measurement tool to assess systematic reviews, systematic review

1. Introduction
A systematic review (SR) is intended to integrate all currently available pieces of evidence that meet the predefined eligibility criteria in order to address a specific research question using specific and systematic methods that have been tested to minimize bias and provide more reliable findings, from which conclusions can be drawn and decisions can be made. Many SRs include meta-analysis, which is a statistical method used to synthesize the
results of several independent studies.\(^\text{[1]}\) SRs/meta-analyses provide the highest level of evidence because they examine all the available evidence instead of individual studies with reproducible and rigorous methods, and evaluate the entire body of evidence to ensure the reliability of the results.\(^\text{[2]}\) With the dissemination of SRs/meta-analyses and training in methodology, the number of SRs/meta-analyses is increasing rapidly; more than 30,000 SRs/meta-analyses were published in 2019. For Cochrane reviews, the annual prevalence of SRs/meta-analyses increased by three-fold from 2004 to 2014.\(^\text{[3]}\) Nevertheless, evidence from a SR/meta-analysis may be limited for use if the methodology or reporting is flawed.\(^\text{[4]}\)

To assess the methodological quality of SRs/meta-analyses, the revised instrument of a measurement tool to assess systematic reviews (AMSTAR-2) tool for assessing SRs, a critical appraisal tool, was published in 2017.\(^\text{[5]}\) To improve the reporting of SRs/meta-analyses, preferred reporting items for systematic reviews and meta-analyses (PRISMA) statements\(^\text{[6]}\) and Meta-Analysis Of Observational Studies in Epidemiology guidelines\(^\text{[7]}\) were published. However, the reporting guidelines were only applied in 29% of SRs, and the rate of compliance to the items of reporting guidelines varied, ranging from 0% to 93%.\(^\text{[3]}\)

The coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2, which has a high case fatality rate (6.3%–15.23%).\(^\text{[8]}\) and has attracted attention worldwide. The number of published studies on COVID-19 is increasing rapidly, and over 10,000 studies have been published since the pandemic. The number of SRs/meta-analyses is also accumulating. Whether the convenient accessibility, rapid publication of studies on COVID-19, and shorter preparation time affect the methodological quality and reporting characteristics of published SRs/meta-analyses, during the specific period of the COVID-19 pandemic, still needs to be clarified. To date, no study has assessed the methodological quality and reporting characteristics of SRs/meta-analyses related to COVID-19. Therefore, this cross-sectional study aimed to investigate the epidemiology, methodological quality, and reporting characteristics of published SRs/meta-analyses related to COVID-19.

### 1. Setting

This cross-sectional study aimed to investigate the epidemiology, methodological quality, and reporting characteristics of published SRs/meta-analyses related to COVID-19. Ethical approval was not required, as this study was cross-sectional in nature and only included SRs and meta-analyses.

### 2. Methods

#### 2.1. Eligibility criteria

According to the definition provided by the Cochrane book, the following criteria were employed: the study is a SR and/or a meta-analysis, or a systematic scoping review, a scoping review, a systematic rapid living review, or a rapid review; the study clearly describes the search strategy; the study explicitly illustrates the study selection criteria and study selection; the study reports the statistical methods to synthesize data including but not limited to heterogeneity assessment, sensitivity analysis, subgroup analysis, and assessment of publication bias if applicable, or the descriptive summary when meta-analysis cannot be performed; and the topic of published SRs/meta-analyses is related to COVID-19 regardless of the specific research theme. SRs/meta-analyses that were published in English or Chinese were included.

Meanwhile, duplicate studies, letters, and study protocols were excluded from the analysis.

#### 2.2. Search strategy

To perform a systematic retrieval of literatures, the Ovid PubMed, Ovid Embase, Cochrane Library, and Web of Science were searched using both Mesh terms and keywords, without language limitations, and the literature search was conducted from January 1, 2019 to April 28, 2020. The search terms used were as follows: “systematic review,” “meta-analysis,” and “COVID-19”; the detailed search strategy can be found in Supplemental Digital Content, http://links.lww.com/MG/G151. The reference lists of included studies were manually checked to identify potential eligible studies.

#### 2.3. Study selection

The study screening was performed in 2 steps: title and abstract screening, and full-text screening. The references retrieved from electronic databases were introduced to Endnote; after removal of duplicates, the studies were exported to the Microsoft Access Database for preliminary screening of titles and abstracts. The full-texts of the remaining studies obtained from the first screening were downloaded and read for further screening based on the study eligibility criteria. The reference lists of all included SRs and meta-analyses were manually checked. Two authors independently screened the studies, and any disagreement was resolved via discussion or adjudication by a third reviewer, if necessary.

#### 2.4. Data extraction

Two authors independently collected the following data: name of the first author; country of the first author; study question; main conclusion; number of authors; journal impact factor; literature retrieval date; date that the study was first available online; focus of review; number of included studies; study design and total number of participants included in the SRs/meta-analyses; risk of bias assessment tool; reporting guidelines mentioned; publication language; literature retrieved; whether the article is a Cochrane review or not; type of review; certainty of evidence based on the Grading of Recommendations Assessment, Development, and Evaluation; funding information; statistic information of the meta-analyses including the software used for data analysis; judgment standards for statistical significance; indicators of data pooling; model for data pooling; method for meta-analysis; statistical method for determining the heterogeneity; method used to assess for publication bias; and additional analyses, like subgroup analysis, sensitivity analysis, and meta-regression. Any disagreement on data extraction was resolved via discussion or adjudication by a third reviewer if necessary.

#### 2.5. Methodological quality assessment

The methodological quality of all included SRs/meta-analyses was assessed using AMSTAR-2,\(^\text{[5]}\) which has a total of 16 items and is used to assess the quality of SRs that enroll both randomized controlled trials (RCTs) and observational studies on
healthcare interventions. Each item is answered by partially yes, yes, or no. The overall quality can be categorized as critically low, low, moderate, or high, based on whether the study has non-critical or critical weakness domains and on the number of noncritical or critical flaw domains. Two authors independently performed the quality assessment, and any disagreement was resolved via discussion or adjudication by a third reviewer, if necessary.

2.6. PRISMA checklist assessment
The reporting information of each study was evaluated based on the PRISMA guidelines; if the information was reported according to the PRISMA checklist, the answer related to this item was yes; otherwise, the answer was no. Two authors independently performed the PRISMA checklist assessment, and any disagreement was resolved via discussion or adjudication by a third reviewer, if necessary.

2.7. Data analysis
The number was counted, and the proportions were calculated. The statistical distribution difference of counts was assessed using a chi-square ($\chi^2$) test. Statistical significance was judged by a $P$ value of <.05 by a two-tailed test. The information of each study was described and summarized in tables.

3. Results
3.1. Study screening results
A total of 319 references were retrieved from the Ovid PubMed (n = 22), Ovid Embase (n = 176), Cochrane Library (n = 2), and Web of Science (n = 119). After removal of duplicates (n = 120), 199 studies underwent title and abstract screening, and 96 studies were excluded. A total of 103 studies underwent full-text reading, and 56 studies were excluded. No eligible studies were identified after manually checking the reference lists of all included studies. Overall, 47 SRs/meta-analyses were included in the final analysis (Fig. 1).

3.2. Epidemiology of included studies
Of the 47 included studies,$^{[9-55]}$ only 13 were SRs,$^{[10,13,18,20,22,23,26,29,38-40,43,52]}$ while 34 were meta-analyses.$^{[9,11-14,16,17,19,21,24,25,27,28,30-37,41,42,44-46,53-55]}$ A total of 17 studies were published by Chinese authors, 8 by Italian authors, and 4 by American authors. Nearly half of the SRs/meta-analyses were performed by <5 authors (n = 20, 42.6%), which was comparable between SRs only (n = 6, 46.2%) and meta-analysis (n = 14, 41.2%); nevertheless, Chinese-based studies (n = 11, 64.7%) were commonly performed by 6 to 10 authors compared with non-Chinese-based studies (n = 7, 23.3%). SRs/meta-analyses were most commonly published by journals with an impact...
factor of no more than 5 (n = 34, 72.3%); and no difference was found between SRs only (n = 9, 14.9%) and meta-analyses (n = 25, 75.5%) or studies performed by Chinese authors (n = 12, 70.6%) or authors outside of China (n = 22, 73.3%) (Table S1, Supplemental Digital Content, http://links.lww.com/MD/G491). The studies mainly focused on the epidemiology (n = 14, 29.8%), clinical manifestations (n = 8, 17.0%), therapeutic interventions (n = 7, 14.9%), prevention (n = 7, 14.9%), diagnosis (n = 6, 12.8%), and prognosis (n = 1, 2.1%); the detailed study aims and main conclusions are listed in Table S2, Supplemental Digital Content, http://links.lww.com/MD/G491. The distribution of review focus was different between SRs only and meta-analysis (χ² = 14.991, P = .015). For SRs, the study focused on the therapeutic interventions (n = 4, 30.8%) and prevention (n = 5, 38.5%); for meta-analysis, epidemiology (n = 13, 38.2%) was the most common topic. For studies published by Chinese authors, the top 2 study topics were epidemiology (n = 6, 35.3%) and clinical manifestations (n = 5, 29.4%); for studies published by authors from other countries, epidemiology (n = 8, 26.7%) was the most common topic. The median number of days from the date of literature retrieval to the date that the study was first available online was comparable between SRs only and meta-analysis (χ² = 2.54, P = .314) and most common ranged from 16 to 30 days. Nevertheless, the period from the date of literature retrieval to the date that the SR/meta-analysis performed by Chinese author was first available online was most common for more than 30 days (n = 8, 47.1%), while that conducted by nonChinese authors ranged from 16 to 30 days (n = 17, 56.7%) (Table S1, Supplemental Digital Content, http://links.lww.com/MD/G491).

### 3.3. General methodological characteristics of included studies

The number of included studies in the SR/meta-analysis was common for <10 (n = 18, 38.3%); the included studies were observational studies (n = 10, 21.3%), case series/case reports (n = 7, 14.9%), and RCTs (n = 3, 6.4%). The most common total number of participants ranged from 1001 to 5000 (n = 26, 55.3%). Several risk of bias assessment tools were used to evaluate the quality of studies included in the reviews, including the Newcastle–Ottawa Scale (NOS) (8, 17.0%), Cochrane risk of bias tool (n = 2, 4.3%), the British National Institute for Clinical Excellence (NICE) (n = 2, 4.3%), Murad tool (n = 2, 4.3%), methodological index for nonrandomized studies MINORS (n = 2, 4.3%), NIH methodological quality tool (n = 2, 4.3%), and others. Most of the studies were conducted in line with the PRISMA guidelines (n = 27, 57.4%) and were published in English (n = 46, 97.9%). The number of databases searched for relevant studies mostly was <6 (n = 44, 93.6%), and manual checking was performed in more than half of the studies (n = 31, 66.0%). Majority of the reviews did not use GRADE to categorize the quality of evidence (n = 40, 85.1%), and most of the reviews reported funding information (n = 34, 72.3%). The distribution of the number of included studies, reporting guidelines mentioned, publication language, number of databases retrieved, manual checking of reference lists, and funding information were comparable between SRs only and meta-analyses or between studies published by Chinese authors and by authors from other countries. The most commonly used study designs were multiple study designs (n = 7, 20.6%) for SRs, observational studies (n = 10, 21.3%) for meta-analyses, and observational studies (n = 7, 41.2%) for SRs only/meta-analyses published by Chinese authors, and multiple study designs (n = 13, 43.3%) for studies published by nonChinese authors (Table 1).

### 3.4. Statistical information regarding meta-analyses

Stata (StataCorp LP, USA) (n = 11, 32.4%), R (The R Foundation for Statistical Computing) (n = 4, 11.8%), and MetaXL (EpiGear International Pty Ltd., Sunrise Beach, Australia) (n = 4, 11.8%) were the statistical software commonly used for performing a meta-analysis. Only 12 (35.3%) studies reported the standard method for determining whether the result was statistically significant or not. The most common indicator to synthesize data was incidence with its 95% confidence interval (CI) (n = 15, 41.1%). A total of 27 (79.5%) studies reported the model used to synthesize data. The different data synthesizing methods used were double arcsine transforming (n = 6, 17.6%), inverse variance model (n = 6, 17.6%), Mantel–Haenszel formula (n = 3, 8.8%), and DerSimonian–Laird procedure (n = 1, 2.9%). Chi-square and F tests were used to investigate the heterogeneity in 20 (58.8%) studies. The methods used to assess the risk of publication bias were Begg test, Egger test, funnel plots, or a combination of these tests. Additional analyses included meta-regression, sensitivity analysis, subgroup analysis, or a combination of these analyses to test the robustness of results or to find the possible source of heterogeneity (Table 2).

### 3.5. Assessment of methodological quality

All included SRs/meta-analyses used the participants, interventions, comparisons, and outcomes principles to construct a research question and the study selection criteria; however, only 14.9% of the included studies (7/47) were performed with a predefined protocol. Over half of the studies (n = 35) included the criteria for selecting a study, and all studies reported the comprehensive literature search strategy. Not all studies included study selection (43/47, 91.3%) and data extraction (35/47, 74.5%) in duplicate, according to the reports provided in the Methods section. Nevertheless, all studies described the included studies in detail, and 97.9% of studies (46/47) justified the reasons for excluding studies during the full-test screening. Nearly half of SRs/meta-analyses (n = 28, 59.6%) had a risk of bias assessment, and only 36.2% (17/47) of the studies interpreted the risk of bias when the results were discussed; meanwhile, none of the included studies reported the sources of funding. A total of 13 studies were SRs only, without data synthesis; therefore, items related to the appropriate statistical methods used for data pooling, the potential impact of risk of bias on the meta-analysis results, satisfactory statements related to the observed heterogeneity, and investigation of publication bias were not applicable; correspondingly, 91.2% (31/34), 29.4% (10/34), 61.8% (21/34), and 67.6% (23/34) of meta-analyses reported the relative items. Approximately 93.6% (44/47) of studies reported the potential source of conflict of interest. Overall, the quality of all included reviews was low to critically low; in particular, 31 (66.0%) studies were rated as having a critically low quality, 13 (27.7%) as having a low quality, and only 3 (6.4%) as having a high quality. Of the 3 high-quality studies, 2 were Cochrane reviews. The detailed descriptions of the SRs only, meta-analysis, studies published by Chinese authors, and studies published by nonChinese authors are listed in Table 3.
3.6. PRISMA checklist assessment

The rate of compliance to the PRISMA guidelines ranged from 14.9% to 100%. All SRs and meta-analyses met the following criteria: provided the rationale and objectives in the Introduction section, indicated the eligibility criteria, and provided the sources of information in the Methods section. The keywords “systematic review” and/or meta-analysis were found in the titles of 44 (93.6%) studies, and a structured summary was included in 41 (87.2%) studies. In the Methods section, the rate of compliance for each item ranged from 14.9% to 100.0%. Only 7 (14.9%) studies provided information on the study protocol and registration, while 15 (31.9%) presented the detailed search

| Category | SR only (n = 13) | SR/Meta (n = 34) | χ2 (P-value) | Published by Chinese author (n = 17) | Published by other country (n = 30) | χ2 (P-value) | Overall (n = 47) |
|----------|-----------------|-----------------|-------------|-----------------------------------|----------------------------------|-------------|-----------------|
| No. of included studies | 2.044 (.526) | | | 0.555 (.907) | | | 18 (38.3%) |
| 0 to 10 | 3 (23.1%) | 15 (44.1%) | 7 (41.2%) | 11 (36.7%) | 18 (38.3%) |
| 11 to 19 | 4 (30.8%) | 6 (17.6%) | 3 (17.6%) | 7 (23.3%) | 10 (21.3%) |
| 20 to 39 | 4 (30.8%) | 8 (23.5%) | 5 (29.4%) | 7 (23.3%) | 12 (25.5%) |
| ≥40 | 2 (15.4%) | 5 (14.7%) | 2 (11.8%) | 5 (16.7%) | 7 (14.9%) |
| Included study design | 9.541 (.031) | | | | 11.421 (.022) | | 11.421 (.022) |
| RCTs | 2 (5.9%) | 1 (2.1%) | 0 (0.0%) | 3 (10.0%) | 3 (6.4%) |
| Observational study | 0 (0.0%) | 10 (21.3%) | 7 (41.2%) | 3 (10.0%) | 10 (21.3%) |
| Case series/case report | 2 (5.9%) | 5 (10.6%) | 4 (23.5%) | 3 (10.0%) | 7 (14.9%) |
| Multiple study design | 7 (20.6%) | 8 (17.0%) | 2 (11.8%) | 13 (43.3%) | 15 (31.9%) |
| NR | 2 (5.9%) | 10 (21.3%) | 4 (23.5%) | 8 (26.7%) | 12 (25.5%) |
| No. of included participants | 26.667 (.000) | | | 5.778 (.295) | | | 5.778 (.295) |
| 0 to 500 | 4 (30.8%) | 2 (5.9%) | 1 (5.9%) | 5 (16.7%) | 6 (12.8%) |
| 501 to 1000 | 3 (23.1%) | 0 (0.0%) | 0 (0.0%) | 3 (10.0%) | 3 (6.4%) |
| 1001 to 5000 | 1 (7.7%) | 8 (23.5%) | 4 (23.5%) | 5 (16.7%) | 9 (19.1%) |
| ≥5001 | 1 (7.7%) | 0 (0.0%) | 0 (0.0%) | 3 (10.0%) | 3 (6.4%) |
| Risk of bias assessment tool used | 10.945 (.219) | | | 21.012 (.013) | | | 21.012 (.013) |
| Mentioned, did not perform | 4 (30.8%) | 3 (8.8%) | 0 (0.0%) | 7 (23.3%) | 7 (14.9%) |
| NOS scale (or modified) | 0 (0.0%) | 8 (23.5%) | 6 (35.3%) | 2 (6.7%) | 8 (17.0%) |
| Cochrane risk of bias tool (or modification) | 0 (0.0%) | 2 (5.9%) | 1 (5.9%) | 1 (3.3%) | 2 (4.3%) |
| NICE | 0 (0.0%) | 2 (5.9%) | 2 (11.8%) | 0 (0.0%) | 2 (4.3%) |
| The Murad tool | 1 (7.7%) | 1 (2.1%) | 0 (0.0%) | 2 (6.7%) | 2 (4.3%) |
| The MINORS | 0 (0.0%) | 2 (5.9%) | 2 (11.8%) | 0 (0.0%) | 2 (4.3%) |
| NIH methodological quality | 1 (7.7%) | 1 (2.1%) | 1 (5.9%) | 1 (3.3%) | 2 (4.3%) |
| Multiple study quality assessment tool | 1 (7.7%) | 3 (8.8%) | 0 (0.0%) | 4 (13.3%) | 4 (8.5%) |
| Other quality assessment tool | 3 (23.1%) | 3 (8.8%) | 1 (5.9%) | 5 (16.7%) | 6 (12.8%) |
| NR | 3 (23.1%) | 9 (26.5%) | 4 (23.5%) | 8 (26.7%) | 12 (25.5%) |
| Reporting guideline mentioned | 3.538 (.316) | | | 7.729 (.052) | | | 7.729 (.052) |
| PRISMA | 10 (76.9%) | 17 (50.0%) | 6 (35.3%) | 21 (70.0%) | 27 (57.4%) |
| MOOSE | 0 (0.0%) | 2 (5.9%) | 2 (11.8%) | 0 (0.0%) | 2 (4.3%) |
| Both PRISMA and MOOSE | 0 (0.0%) | 3 (8.8%) | 1 (5.9%) | 2 (6.7%) | 3 (23.1%) |
| NR | 3 (23.1%) | 12 (35.3%) | 8 (47.1%) | 7 (23.3%) | 15 (31.9%) |
| Publication language | 0.391 (1.000) | | | 1.803 (.362) | | | 1.803 (.362) |
| Chinese | 0 (0.0%) | 1 (2.9%) | 1 (5.9%) | 0 (0.0%) | 1 (2.1%) |
| English | 13 (100.0%) | 33 (97.1%) | 16 (94.1%) | 30 (100.0%) | 46 (97.9%) |
| No of databases retrieved | 1.244 (.537) | | | 0.745 (.689) | | | 0.745 (.689) |
| ≤3 | 7 (53.8%) | 16 (47.1%) | 7 (41.2%) | 16 (53.3%) | 23 (48.9%) |
| 4 to 6 | 6 (46.2%) | 15 (44.1%) | 9 (52.9%) | 12 (40.0%) | 21 (44.7%) |
| ≥7 | 0 (0.0%) | 3 (8.8%) | 1 (5.9%) | 2 (6.7%) | 3 (23.1%) |
| Manually checking of reference lists | 0.156 (.693) | | | 0.019 (.892) | | | 0.019 (.892) |
| Yes | 8 (61.5%) | 23 (67.6%) | 11 (64.7%) | 20 (66.7%) | 31 (66.0%) |
| No | 5 (38.5%) | 11 (32.4%) | 6 (35.3%) | 10 (33.3%) | 16 (34.0%) |
| GRADE assessment of evidence | 3.573 (.059) | | | 4.661 (.031) | | | 4.661 (.031) |
| Yes | 4 (30.8%) | 3 (8.8%) | 0 (0.0%) | 7 (23.3%) | 7 (14.9%) |
| NR | 9 (69.2%) | 31 (91.2%) | 17 (100.0%) | 23 (76.7%) | 40 (85.1%) |
| Funding | 0.649 (.723) | | | 0.882 (.471) | | | 0.882 (.471) |
| Yes | 6 (46.2%) | 13 (38.2%) | 9 (52.9%) | 10 (33.3%) | 19 (40.4%) |
| No | 3 (23.1%) | 12 (35.3%) | 4 (23.5%) | 11 (36.7%) | 15 (31.9%) |
| NR | 4 (30.8%) | 9 (26.5%) | 4 (23.5%) | 9 (30.0%) | 13 (27.7%) |

Meta = meta-analysis, MOOSE = preferred reporting items for meta-analyses of observational studies in epidemiology statement, NICE = the British National Institute for Clinical Excellence, No. = number, NOS = Newcastle–Ottawa Scale, NR = not reported, PRISMA = preferred reporting items for systematic reviews and meta-analysis statement, RCTs = randomized controlled trials, the MINORS = the methodological index nonrandomized study statement, the Murad tool = the framework for appraisal, synthesis and application of evidence suggested by Murad et al, SR = systematic review.
strategy. Nearly half of the studies assessed the publication bias (n = 21, 44.7%) and performed an additional analysis (n = 23, 48.9%). More than half of the studies involved a study selection process (n = 43, 91.5%) or data collection process (n = 35, 74.5%), included the same data items (n = 35, 74.5%), assessed the risk of bias in individual studies (n = 29, 61.7%), provided summary measures (n = 45, 95.7%), and synthesized the results (n = 32, 68.1%). In the Results section, the rate of compliance to each of the items ranged from 42.6% to 97.9%. The risk of bias in less than half of the studies was similar to that within studies (n = 21, 44.7%), across studies (n = 20, 42.6%), and in additional analyses (n = 22, 46.8%); meanwhile, more than half of the studies performed the study selection process (n = 46, 97.9%), had similar study characteristics (n = 40, 85.1%), reported the results of individual studies (n = 43, 91.5%), and synthesized the results (n = 34, 72.4%). In the Discussion section, more than half of studies provided the summary of evidence (n = 42, 89.4%), limitations (n = 43, 91.5%), and conclusions (n = 43, 91.5%). With regard to the funding source, 34 (72.3%) studies reported this information in accordance with the PRISMA guidelines. The detailed descriptions of the SRs only, meta-analyses, studies published by Chinese authors, and studies published by non-Chinese authors are listed in Table 4.

### Table 2

| Characteristic                          | Statistic software | Reporting standards for statistical significance | Indicator to synthesize data | Meta-analysis model used | Meta-analysis method used | Statistical heterogeneity investigated | Risk of publication bias assessed | Additional analyses |
|-----------------------------------------|--------------------|--------------------------------------------------|-----------------------------|--------------------------|----------------------------|---------------------------------------|----------------------------------|-------------------|
| Statistic software                      | Stata              | Yes, a 2-sided P-value of ≤ .05 was deemed significant | Incidence with 95% CI       | A fixed or random effect model based on heterogeneity | Double arcsine method        | Chi square and I^2 tests               | Begg test                | Meta-regression    |
|                                         | R                  |                                                   | OR with 95% CI              | A fixed or random effect model based on heterogeneity | An inverse variance model    |                                       | Egger test              | Sensitivity analysis |
|                                         | MetaXL             |                                                   | RR with 95% CI              | A fixed or random effect model based on heterogeneity | Mantel–Haenszel formula     |                                       | Funnel plot             | Subgroup analysis   |
|                                         | Comprehensive Meta Analysis |                           | >2 indicators               | A fixed or random effect model based on heterogeneity | DerSimonian–Laird procedure |                                       | Begg test, Egger test, and Funnel plots | Meta-regression and sensitivity analysis |
|                                         | Review Manager     |                                                   | NR                          | A fixed or random effect model based on heterogeneity | Reporting >1 method         |                                       | Egger test, and Funnel plots | Sensitivity analysis and subgroup analysis |
|                                         | StatsDirect        |                                                   | NR                          | A fixed or random effect model based on heterogeneity | NR                         |                                       | Egger test, Harbord test, and inverted plot analysis | Sensitivity and meta-regression |
|                                         | >1 software        |                                                   | NR                          | A fixed or random effect model based on heterogeneity | NR                         |                                       | NR                   | Others |
|                                         | NR                 |                                                   | NR                          | A fixed or random effect model based on heterogeneity | NR                         |                                       | NR                  | >2 additional analyses |
|                                         | 1 (2.9%)           |                                                   | NR                          | A fixed or random effect model based on heterogeneity | 1 (2.9%)                   |                                       | 1 (2.9%)               | 1 (2.9%) |
|                                         | 11 (32.4%)         |                                                   | 8 (23.5%)                   | A fixed or random effect model based on heterogeneity | 3 (8.8%)                   |                                       | 1 (2.9%)               | 11 (32.4%) |
|                                         | 1 (2.9%)           |                                                   | 6 (17.6%)                   | A fixed or random effect model based on heterogeneity | 6 (17.6%)                  |                                       | 1 (2.9%)               | 1 (2.9%) |
|                                         | 1 (2.9%)           |                                                   | 9 (26.5%)                   | A fixed or random effect model based on heterogeneity | 6 (17.6%)                  |                                       | 1 (2.9%)               | 1 (2.9%) |
|                                         | 1 (2.9%)           |                                                   | 2 (5.9%)                    | A fixed or random effect model based on heterogeneity | 3 (8.8%)                   |                                       | 1 (2.9%)               | 1 (2.9%) |
|                                         | 1 (2.9%)           |                                                   | 3 (8.8%)                    | A fixed or random effect model based on heterogeneity | 2 (5.9%)                   |                                       | 1 (2.9%)               | 1 (2.9%) |
|                                         | 1 (2.9%)           |                                                   | 1 (2.9%)                    | A fixed or random effect model based on heterogeneity | 2 (5.9%)                   |                                       | 1 (2.9%)               | 1 (2.9%) |
|                                         | 1 (2.9%)           |                                                   | 6 (17.6%)                   | A fixed or random effect model based on heterogeneity | 3 (8.8%)                   |                                       | 1 (2.9%)               | 1 (2.9%) |
|                                         | 1 (2.9%)           |                                                   | 1 (2.9%)                    | A fixed or random effect model based on heterogeneity | 2 (5.9%)                   |                                       | 1 (2.9%)               | 1 (2.9%) |
|                                         | 1 (2.9%)           |                                                   | 6 (17.6%)                   | A fixed or random effect model based on heterogeneity | 1 (2.9%)                   |                                       | 1 (2.9%)               | 1 (2.9%) |
|                                         | 1 (2.9%)           |                                                   | 3 (8.8%)                    | A fixed or random effect model based on heterogeneity | 2 (5.9%)                   |                                       | 1 (2.9%)               | 1 (2.9%) |
|                                         | 1 (2.9%)           |                                                   | 1 (2.9%)                    | A fixed or random effect model based on heterogeneity | 2 (5.9%)                   |                                       | 1 (2.9%)               | 1 (2.9%) |
|                                         | 11 (32.4%)         |                                                   | 6 (17.6%)                   | A fixed or random effect model based on heterogeneity | 1 (2.9%)                   |                                       | 1 (2.9%)               | 1 (2.9%) |

CI = confidence interval, NR = not reported, OR = odds ratio, RR = relative risk.

### 4. Discussion

This cross-sectional study investigated the methodological quality and reporting characteristics of published SRs and
meta-analyses related to COVID-19. Overall, the study quality was low to critically low, and the rate of compliance to the PRISMA guidelines varied from 14.9% to 100%. As the first COVID-19 outbreak occurred in China, the number of studies performed by Chinese authors was relatively high. The median number of days from the date of literature retrieval to the date that the study was first available online was 21 days; due to the limited time, only 7 studies had study protocols.

Various risk of bias assessment tools were used in different SRs/meta-analyses; this was due to the fact that SRs/meta-analyses focused on several topics such as epidemiology, therapeutic interventions, prevention, diagnosis, and prognosis. The following methodological quality assessment tools were recommended, based on the study designs: \( ^{[54]} \) the Cochrane Collaboration’s tool for RCTs, the Newcastle–Ottawa Scale for cohort and case-control studies, the methodological index for nonrandomized studies for nonrandomized interventional studies, the Agency for Healthcare Research and Quality methodology checklist for cross-sectional studies, the Quality Assessment of Diagnostic Accuracy Studies-2 for diagnostic accuracy test studies, the Systematic Review Centre for Laboratory animal Experimentalation for animal studies, the revised version of the AMSTAR for SRs/meta-analyses, an 18-item tool for case series studies, and the Appraisal of Guidelines Research and Evaluation-II instrument for clinical practice guidelines.

In this study, none of the SRs/meta-analyses reported the sources of funding of the studies included in the review. Although this is only a noncritical weakness item and does not dramatically affect the methodological quality, it had associations with the published journal impact factor. \( ^{[55]} \) This may be partially

### Table 3

| Study quality assessment item (Yes) | SR only \((n=13)\) | SR/meta \((n=34)\) | Published by Chinese author \((n=17)\) | Published by other country \((n=30)\) | Overall \((n=47)\) |
|-----------------------------------|----------------|----------------|----------------|----------------|----------------|
| 1. Did the research questions and inclusion criteria for the review include the components of PICO? | 13 (100.0%) | 34 (100.0%) | 17 (100.0%) | 30 (100.0%) | 47 (100.0%) |
| 2*. Did the report of the review contain an explicit statement that the review methods were established prior to the conduct of the review and did the report justify any significant deviations from the protocol? | 3 (23.1%) | 11 (32.4%) | 0 (0.0%) | 7 (23.2%) | 7 (14.9%) |
| 3. Did the review authors explain their selection of the study designs for inclusion in the review? | 9 (69.2%) | 26 (76.5%) | 14 (82.4%) | 21 (70.0%) | 35 (74.5%) |
| 4. Did the review authors use a comprehensive literature search strategy? | 13 (100.0%) | 34 (100.0%) | 17 (100.0%) | 30 (100.0%) | 47 (100.0%) |
| 5. Did the review authors perform study selection in duplicate? | 12 (92.3%) | 31 (91.2%) | 14 (82.4%) | 29 (96.7%) | 43 (91.5%) |
| 6. Did the review authors perform data extraction in duplicate? | 10 (76.9%) | 25 (73.5%) | 11 (64.7%) | 24 (80.0%) | 35 (74.5%) |
| 7. Did the review authors provide a list of excluded studies and justify the exclusions? | 12 (92.3%) | 34 (100.0%) | 17 (100.0%) | 29 (96.7%) | 46 (97.9%) |
| 8. Did the review authors describe the included studies in adequate detail? | 13 (100.0%) | 34 (100.0%) | 17 (100.0%) | 30 (100.0%) | 47 (100.0%) |
| 9*. Did the review authors use a satisfactory technique for assessing the risk of bias (RoB) in individual studies that were included in the review? | 6 (46.2%) | 22 (64.7%) | 13 (76.5%) | 15 (50.0%) | 28 (59.6%) |
| 10. Did the review authors report on the sources of funding for the studies included in the review? | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| 11*. If meta-analysis was performed, did the review authors use appropriate methods for statistical combination of results? | Not applicable | 31 (91.2%) | 15 (88.2%) | 16 (53.3%) | 31 (66.0%) |
| 12. If meta-analysis was performed, did the review authors assess the potential impact of RoB in individual studies on the results of the meta-analysis or other evidence synthesis? | Not applicable | 10 (29.4%) | 3 (17.6%) | 7 (23.3%) | 10 (21.2%) |
| 13*. Did the review authors account for RoB in primary studies when interpreting/discussing the results of the review? | 5 (38.5%) | 12 (35.3%) | 6 (35.3%) | 11 (36.7%) | 17 (36.2%) |
| 14. Did the review authors provide a satisfactory explanation for, and discussion of, any heterogeneity observed in the results of the review? | Not applicable | 21 (61.8%) | 9 (52.9%) | 12 (40.0%) | 21 (44.7%) |
| 15*. If they performed quantitative synthesis did the review authors carry out an adequate investigation of publication bias (small study bias) and discuss its likely impact on the results of the review? | Not applicable | 23 (67.6%) | 14 (82.4%) | 9 (30.0%) | 23 (48.9%) |
| 16. Did the review authors report any potential sources of conflict of interest, including any funding they received for conducting the review? | 11 (84.6%) | 33 (97.1%) | 17 (100.0%) | 27 (90.0%) | 44 (93.6%) |

| Rating overall confidence | High | Low | Critically low |
|---------------------------|-----|-----|---------------|
|                           | 2 (15.4%) | 1 (2.9%) | 0 (0.0%) |
|                           | 4 (30.8%) | 9 (26.5%) | 5 (29.4%) |
|                           | 7 (53.8%) | 24 (70.6%) | 12 (70.6%) |

PICO = participants, interventions, comparisons, outcomes.

* Critical weakness domains.
and reporting should be improved. Secondly, due to the limited study showed similar results and concluded that the performance compared with the study performed by Page et al in 2014,[3] our logical quality, and reporting characteristics of SRs/meta-analyses related to COVID-19 1 author; for institutional conflict of interest, the percentage of previous studies that reported this information was 41.4%).[59] The conduct and reporting quality of SRs/meta-analyses on COVID-19 were poor, which should be improved. The funding information of studies included in the SRs/meta-analyses should be reported.

5. Conclusions
This study aimed to evaluate the methodological quality and reporting characteristics of SRs/meta-analyses on COVID-19. However, the conduct and reporting quality of SRs/meta-analyses on COVID-19 were poor, which should be improved. The funding information of studies included in the SRs/meta-analyses should be reported.

Author contributions
Conceptualization: Yuehong Chen, Geng Yin, Qibing Xie.
Data curation: Yuehong Chen, Ling Li, Qiuping Zhang, Huan Liu, Sang Lin.
Formal analysis: Yuehong Chen, Ling Li, Yupeng Huang.
Funding acquisition: Yuehong Chen, Qibing Xie.
Investigation: Yuehong Chen, Qiuping Zhang, Huan Liu, Yupeng Huang, Sang Lin.
Methodology: Yuehong Chen, Ling Li, Huan Liu, Yupeng Huang, Sang Lin.
Project administration: Yuehong Chen, Qiuping Zhang, Yupeng Huang, Geng Yin.
Resources: Geng Yin, Qibing Xie.

Table 4
Preferred reporting items for systematic review and meta-analysis assessment of reporting characteristics.

| Category                  | Item (Yes) |
|---------------------------|------------|
|                          | SR only (n = 13) | SR/meta (n = 34) | Published by Chinese author (n = 17) | Published by other country (n = 30) | Overall (n = 47) |
| Title                     | 13 (100.0%) | 31 (91.2%) | 16 (94.1%) | 28 (93.3%) | 44 (93.6%) |
| Abstract                  | 11 (84.6%) | 30 (88.2%) | 15 (88.2%) | 26 (86.7%) | 41 (87.2%) |
| Introduction              | 13 (100.0%) | 34 (100.0%) | 17 (100.0%) | 30 (100.0%) | 47 (100.0%) |
| 4. Objectives             | 13 (100.0%) | 34 (100.0%) | 17 (100.0%) | 30 (100.0%) | 47 (100.0%) |
| Methods                   | 3 (23.1%) | 4 (11.8%) | 0 (0.0%) | 7 (23.3%) | 7 (14.9%) |
| 5. Protocol and registration | 13 (100.0%) | 34 (100.0%) | 17 (100.0%) | 30 (100.0%) | 47 (100.0%) |
| 6. Eligibility criteria   | 13 (100.0%) | 34 (100.0%) | 17 (100.0%) | 30 (100.0%) | 47 (100.0%) |
| 7. Information sources    | 13 (100.0%) | 34 (100.0%) | 17 (100.0%) | 30 (100.0%) | 47 (100.0%) |
| 8. Search                 | 9 (69.2%) | 6 (17.6%) | 2 (11.8%) | 13 (43.3%) | 15 (31.9%) |
| 9. Study selection        | 13 (100.0%) | 30 (88.2%) | 13 (76.5%) | 30 (100.0%) | 43 (91.5%) |
| 10. Data collection process | 9 (69.2%) | 26 (76.5%) | 12 (70.6%) | 23 (76.7%) | 35 (74.5%) |
| 11. Data items            | 10 (76.9%) | 25 (73.5%) | 13 (76.5%) | 22 (73.3%) | 35 (74.5%) |
| 12. Risk of bias in individual studies | 7 (53.8%) | 22 (64.7%) | 13 (76.5%) | 16 (53.3%) | 29 (61.7%) |
| 13. Summary measures      | 12 (92.3%) | 33 (97.1%) | 17 (100.0%) | 28 (93.3%) | 45 (95.7%) |
| 14. Synthesis of results  | 0 (0.0%) | 32 (94.1%) | 16 (94.1%) | 16 (53.3%) | 32 (68.1%) |
| 15. Risk of bias across studies | 0 (0.0%) | 21 (61.8%) | 13 (76.5%) | 8 (26.7%) | 21 (44.7%) |
| 16. Additional analyses   | 0 (0.0%) | 23 (67.6%) | 12 (70.6%) | 11 (36.7%) | 23 (48.9%) |
| Results                   | 17 (100.0%) | 32 (97.1%) | 17 (100.0%) | 29 (96.7%) | 46 (97.9%) |
| 17. Study selection       | 11 (84.6%) | 28 (85.3%) | 13 (76.5%) | 27 (92.3%) | 40 (85.1%) |
| 18. Study characteristics | 11 (84.6%) | 29 (85.3%) | 13 (76.5%) | 27 (92.3%) | 40 (85.1%) |
| 19. Risk of bias within studies | 6 (46.2%) | 15 (44.1%) | 9 (52.9%) | 12 (40.0%) | 21 (44.7%) |
| 20. Results of individual studies | 11 (84.6%) | 32 (94.1%) | 15 (88.2%) | 28 (93.3%) | 43 (91.5%) |
| 21. Synthesis of results  | 0 (0.0%) | 34 (100.0%) | 17 (100.0%) | 17 (56.7%) | 34 (72.3%) |
| 22. Risk of bias across studies | 0 (0.0%) | 20 (58.8%) | 11 (64.7%) | 9 (30.0%) | 20 (42.6%) |
| 23. additional analyses   | 0 (0.0%) | 22 (64.7%) | 11 (64.7%) | 11 (36.7%) | 22 (46.8%) |
| Discussion                | 11 (84.6%) | 31 (91.2%) | 17 (100.0%) | 25 (83.3%) | 42 (89.4%) |
| 25. Limitations           | 9 (69.2%) | 34 (100.0%) | 17 (100.0%) | 26 (86.7%) | 43 (91.5%) |
| 26. Conclusions           | 12 (92.3%) | 31 (91.2%) | 14 (82.4%) | 29 (96.7%) | 43 (91.5%) |
| Funding                   | 9 (69.2%) | 25 (73.5%) | 12 (70.6%) | 22 (73.3%) | 34 (72.3%) |

influenced by the shorter manuscript preparation time, although the rate of reporting of funding sources in meta-analyses of trials on pharmacological treatment in high-impact biomedical journals was low (7%).[58] For individual conflicts of interest, 49% and 33% of Cochrane and non-Cochrane reviews, respectively, reported the type of conflict of interest for at least 1 author; for institutional conflicts of interest, the rate of reporting was lesser: 19% and 5% for Cochrane and non-Cochrane reviews, respectively.[8]

With regard to the compliance to the PRISMA guidelines, the number of items related to the risk of bias within studies and the risk of bias across studies were higher for the Methods section than for the Results section; this finding indicated that some SRs/meta-analyses did not report the risk of bias within studies and across studies in the Results section, although the methodology was reported in the Methods section. Other reporting items, like the detailed search strategy and performance of additional analysis, need to be improved. In our study, 72.3% of SRs/meta-analyses reported the funding information, which was similar to the percentage of previous studies that reported this information (64%[1] but higher than 41.4%).[59]

This cross-sectional study was the first to assess the study quality of published SRs/meta-analyses related to COVID-19 regardless of the study topic. This study has several limitations. Firstly, we did not compare the study characteristics, methodological quality, and reporting characteristics of SRs/meta-analyses on COVID-19 with those of studies investigating other topics published during the same period. Nevertheless, when compared with the study performed by Page et al in 2014,[3] our study showed similar results and concluded that the performance and reporting should be improved. Secondly, due to the limited time to conduct the reviews, only 7 studies had a study protocol, which is one of the critical domains in the study quality assessment tool, AMSTAR-2; thus, the study quality was considered low if the reviews did not have a study protocol; only 3 (6.4%) studies were Cochrane reviews. In addition, none of the original studies included in the SRs/meta-analyses reported the funding information.
Software: Yuehong Chen.
Supervision: Geng Yin, Qibing Xie.
Validation: Yuehong Chen, Ling Li, Qiuping Zhang, Huan Liu, Sang Lin, Geng Yin, Qibing Xie.
Visualization: Yuehong Chen.
Writing – original draft: Yuehong Chen, Ling Li, Qiuping Zhang, Huan Liu, Yupeng Huang, Sang Lin, Geng Yin, Qibing Xie.
Writing – review & editing: Yuehong Chen, Ling Li, Qiuping Zhang, Huan Liu, Yupeng Huang, Sang Lin, Geng Yin, Qibing Xie.

References

[1] Higgins, J.P.T. and S. Green, Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. Chapter 1: Introduction, systematic reviews. The Cochrane Collaboration, 2011.

[2] Murad MH, Montori VM. Synthesizing evidence: shifting the focus from individual studies to the body of evidence. JAMA 2013;309:2217–8.

[3] Page MJ, Shamseer L, Altman DG, Tetzlaff J, Sampson M. Epidemiology and reporting characteristics of systematic reviews of biomedical research: a cross-sectional study. PLoS Med 2016;13:e1002028.

[4] Glasziou P, Altman DG, Bossuyt P, et al. Reducing waste from incomplete or unusable reports of biomedical research. Lancet 2014;383:267–76.

[5] Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ 2017;358:j4008.

[6] Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009;151:264–9, w64.

[7] Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000;283:2008–12.

[8] Bult C, Kato Y. Epidemiology of COVID-19. Turk J Med Sci 2020;50:563–70.

[9] Aggarwal G, Lippi G, Michael Henry B. Cerebrovascular disease is associated with an increased disease severity in patients with coronavirus disease 2019 (COVID-19): a pooled analysis of published literature. Int J Stroke 2020;15:385–9.

[10] AminJafari A, Ghassemi S. The possibility of immunotherapy for COVID-19: a systematic review. Int Immunopharmacol 2020;83:106455.

[11] Bao C, Liu X, Zhang H, Li Y, Liu J. Coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. Adv Ther 2020;37:104371.

[12] Bartoszko JJ, Farooqi MAM, Alhazzani W, Loeb M. Medical masks vs N95 respirators for preventing COVID-19 in healthcare workers: a systematic review and meta-analysis of randomized trials. Influenza Other Respir Viruses 2020;14:365–73.

[13] Borges do Nascimento IF, Cacci N, Abdalazeeem HM. Novel coronavirus infection (COVID-19) in humans: a scoping review and meta-analysis. J Clin Med 2020;9:941.

[14] Cao Y, Liu X, Xiong L, Cai K. Imaging and clinical features of patients with 2019 novel coronavirus disease (SARS-CoV-2): a systematic review and meta-analysis. J Med Virol 2020;92:1149.

[15] Ceravolo MG, De Sire A, Andrenelli E, Negrini F, Negrini S. Systematic rapid “living” review on rehabilitation needs due to covid-19: update to March 31st 2020. Eur J Phys Rehabil Med 2020;56:347.

[16] Chang TH, Wu JL, Chang LY. Clinical characteristics and diagnostic challenges of pediatric COVID-19: a systematic review and meta-analysis. J Formos Med Assoc 2020;119:982–9.

[17] Cheung KS, Hung IF, Chan PP, et al. Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from the Hong Kong cohort and systematic review and meta-analysis. Gastroenterology 2020;159:81.

[18] Couper K, Taylor-Phillips S, Grove A, et al. COVID-19 in cardiac arrest and infection risk to rescuers: a systematic review. Resuscitation 2020;151:59–66.

[19] Di Mascio D, Khalil A, Saccone G, et al. Outcome of Coronavirus spectrum infections (SARS, MERS, COVID-19) during pregnancy: a systematic review and meta-analysis. Am J Obstet Gynecol MFM 2020;2:100107.

[20] Elshafeey F, Magdi R, Hindi N, et al. A systematic scoping review of COVID-19 during pregnancy and childbirth. Int J Gynaecol Obstet 2020;150:47.

[21] Emami A, Javanmardi F, Piriboneh Y, Akbari A. Prevalence of underlying diseases in hospitalized patients with COVID-19: a systematic review and meta-analysis. Arch Acad Emerg Med 2020;8:e35.

[22] Elkind SN, Bone AE, Lovell N, et al. The role and response of palliative care and hospice services in epidemics and pandemics: a rapid review to inform practice during the COVID-19 pandemic. J Pain Symptom Manage 2020;60:e31.

[23] Ford N, Vitoria M, Rangaraj A, Norris SL. Systematic review of the efficacy and safety of antiretroviral drugs against SARS. MERS or COVID-19: initial assessment 2020;23:e25489.

[24] Fu L, Wang B, Yuan T, et al. Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: a systematic review and meta-analysis. J Infect 2020;80:656–65.

[25] Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chim Lab Med 2020;58:1021.

[26] Houghton C, Meskell P, Delaney H, et al. Barriers and facilitators to healthcare workers’ adherence with infection prevention and control (IPC) guidelines for respiratory infectious diseases: a rapid qualitative evidence synthesis. Cochrane Database Syst Rev 2020;4:CD013382.

[27] Hu Y, Sun J, Dai Z, et al. Prevalence and severity of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. J Clin Virol 2020;127:104371.

[28] Huang I, Lin MA, Pranata R. Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia – a systematic review, meta-analysis, and meta-regression. Diabetes Metab Syndr 2020;14:395–403.

[29] Jayawardena R, Sooriyarachchi P, Chourdakis M, Jeewandara C, Nandasinge P. Enhancing immunity in viral infections, with special emphasis on COVID-19: a review. Diabetes Metab Syndr 2020;14:367–82.

[30] Kim H, Hong H. Diagnostic performance of CT and reverse transcriptase-polymerase chain reaction for coronavirus disease 2019: a meta-analysis. Radiology 2020;296:1E145.

[31] Li B, Yang J, Zhao F, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol 2020;109:531–8.

[32] Li JW, Han TW, Woodward M, et al. The impact of 2019 novel coronavirus on heart injury: a systematic review and meta-analysis. Prog Cardiovasc Dis 2020;63:518.

[33] Li IQ, Huang T, COVID-19 patients’ clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol 2020;92:577.

[34] Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis. Clin Chim Acta 2020;506:145–8.

[35] Lippi G, Wong J, Henry BM. Hypertension in patients with coronavirus disease 2019 (COVID-19): a pooled analysis. Pol Arch Intern Med 2020;130:304–9.

[36] Loffredo L, Pacella F. Conjunctivitis and COVID-19: a meta-analysis. J Med Virol 2020;doi: 10.1002/jmv.25938.

[37] Mantovani A, Beatrice G, Dalbeni A. Coronavirus disease 2019 and prevalence of chronic liver disease: a meta-analysis 2020;40:1316–20.

[38] Nauhausstra-Steir B, Mayr V, Dobrcuse AL, et al. Quarantine alone or in combination with other public health measures to control COVID-19: a rapid review. Cochrane Database Syst Rev 2020;4:CD013574.

[39] Parazzini F, Bortolus R, Mauri PA, Favilli A, Gerli S, Ferrazzi E. Delivery in pregnant women infected with SARS-CoV-2: a fast review. Int J Gynaecol Obstet 2020;150:41.

[40] Park M, Cook AR, Lim JT. A systematic review of COVID-19 epidemiology based on current evidence. J Clin Med 2020;9:104354.

[41] Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, et al. Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis. Travel Med Infect Dis 2020;34:101623.

[42] Roncon I, Zuin M, Rigatteri G, Zuliani G. Diabetic patients with COVID-19 infection are at higher risk of ICU admission and poor short-term outcome. J Clin Med 2020;12:104354.

[43] Salehi S, Abedi A, Balakrishnan S, Gholamezanezhad A, Coronavirus disease 2019 (COVID-19): a systematic review of imaging findings in 919 patients. AJR Am J Roentgenol 2020;215:1–7.
[44] Santoso A, Pranata R, Wibowo A, Al-Farabi MJ, Huang I, Antariksa B. Cardiac injury is associated with mortality and critically ill pneumonia in COVID-19: a meta-analysis. Am J Emerg Med 2020.

[45] Sarma P, Kaur H. Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: A systematic review and meta-analysis 2020;44:352.

[46] Sun P, Qie S, Liu Z, Ren J, Li K, Xi J. Clinical characteristics of hospitalized patients with SARS-CoV-2 infection: a single arm meta-analysis. J Med Virol 2020;92:612.

[47] Verbeek JH, Rajamaki B, Ijaz S, et al. Personal protective equipment for preventing highly infectious diseases due to exposure to contaminated body fluids in healthcare staff. Cochrane Database Syst Rev 2020;5: Cd011621.

[48] Wang B, Li R, Lu Z, Huang Y. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging (Albany NY) 2020;12:6049–57.

[49] Wu YY, Li H, Xu XB, Zheng KX, Qi XS, Guo XZ. Clinical features and outcome of treatment for novel coronavirus pneumonia: a meta-analysis. Zhonghua Gan Zang Bing Za Zhi 2020;28:240–6.

[50] Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis 2020;94:91–5.

[51] Yang Z, Liu J, Zhou Y, Zhao X, Zhao Q, Liu J. The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis. J Infect 2020;81:e13.

[52] Zaigham M, Andersson O. Maternal and perinatal outcomes with COVID-19: a systematic review of 108 pregnancies. Acta Obstet Gynecol Scand 2020;99:823.

[53] Zhao Q, Meng M. The impact of COPD and smoking history on the severity of COVID-19: a systemic review and meta-analysis. J Med Virol 2020;92:1915.

[54] Zhu J, Ji P, Pang J, et al. Clinical characteristics of 3,062 COVID-19 patients: a meta-analysis. J Med Virol 2020;92:1902.

[55] Zhu J, Zhong Z, Li H, et al. CT imaging features of 4121 patients with COVID-19: a meta-analysis. J Med Virol 2020;92:891.

[56] Zeng X, Zhang YG, Kwong Joey SW, et al. The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review. J Evid Based Med 2015;8:2–10.

[57] Hakoum MB, Anouti S, Al-Gibbawi M, Abou-Jaoude EA, Hasbani DJ, Lopes LC. Reporting of financial and non-financial conflicts of interest by authors of systematic reviews: a methodological survey 2016;6: e011997.

[58] Roseman M, Milette K, Bero LA, et al. Reporting of conflicts of interest in meta-analyses of trials of pharmacological treatments. JAMA 2011; 305:1008–17.

[59] Yang M, Jiang L, Wang A, Xu G. Epidemiology characteristics, reporting characteristics, and methodological quality of systematic reviews and meta-analyses on traditional Chinese medicine nursing interventions published in Chinese journals. Int J Nurs Pract 2017;23:1.